References
- National Committee for Clinical Laboratory Standards. (NCCLS) Approved Standard M7-A2. Methods for dilution antimicrobial susceptibility test for bacteria that grow aerobically, Second Edition. National Committee for Clinical Laboratory Standards, Villanova, Pa, 1990.
- National Committee for Clinical Laboratory Standards. (NCCLS) Fourth Informational Supplement M100-S4. Performance Standards for Antimicrobial Susceptibility Testing. National Committee for Clinical Laboratory Standards, Villanova, Pa, 1992.
- Fass RJ. In vitro activity of ciprofloxacin (Bay o 9867). Antimicrob Agents Chemother 1983; 24 :568–74.
- King A, Phillips I. The comparative in-vitro activity of eight newer quinolones and nalidixic acid. J Antimicrob Chemother 1986; 18(Suppl D): 1–20.
- Phillips I, King A, Shanno n K. In vitro properties of the quinolones. In: Andriole VT ed. The Quinolones. London: Academic Press, 1988: 83–117.
- Barry AL, Fuchs PC. Cross-resistance and cross- susceptibility between fluoroquinolone agents. Eur J Clin Microbiol Infect Dis 1991; 10: 1013–18.
- Cooper MA, Andrews JM, Ashby JP, Matthews RS, Wise R. In-vitro activity of sparfloxacin, a new quinolone antimicrobial agent. J Antimicrob Chemother 1990; 26: 667–76.
- King AL, Bethune L, Phillips I. The in-vitro activity of tosufloxacin, a new fluorinated quinolone, compared with that of ciprofloxacin and temafloxacin. J Antimicrob Chemother 1991; 28: 719–25.
- Fass RJ. In vitro activity of Bay y 3118, a new quinolone. Antimicrob Agents Chemother 1993; 37: 2348–57.
- Crumplin GC: Mechanisms of resistance to the 4-quinolone antibacterial agents. J Antimicrob Chemother 1990; 26 (Suppl F): 131–44.
- Thomson KS, Sanders CC, Hayden ME. In vitro studies with five quinolones: evidence for changes in relative potency as quinolone resistance rises. Antimicrob Agents Chemother 1991; 35: 2329–34.